HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study ID
NCT06769425
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Breast Cancer
  • Advanced Gastric Cancer
  • Advanced Prostate Cancer
  • HER2-negative
  • Recurrent Ovarian Cancer
  • TNBC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Key Dates

Start date
May 7, 2025
Status verified
Jun 2025
Primary completion
May 7, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
157 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Advanced prostate cancer
  • Experimental: Cohort 2
    Advanced prostate cancer or solid tumor
  • Experimental: Cohort 3
    Advanced HER2-negative breast cancer or recurrent ovarian cancer
  • Experimental: Cohort 4
    Recurrent ovarian cancer
  • Experimental: Cohort 5
    Platinum-sensitive recurrent ovarian cancer
  • Experimental: Cohort 6
    Advanced gastric cancer or solid tumor
  • Experimental: Cohort 7
    HRD positive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Primary Outcome Measure

Maximum tolerated dose (MTD) of HS-10502（Stage 1：Dose escalating stage） [ Time Frame: Cycle 1 (21 days) ]

Central Contacts

Related Studies